TLRY
Tilray Brands, Inc.$3.98-0.15 (-3.74%)Prev Close$4.14·MCap$463.0M·P/E—·Vol2.48M·Yield—
▲
Buys (12M)
3
$69.2K
▼
Sells (12M)
1
$232.9K
◆
Net Activity
Net Seller
$163.7K
●
Active Insiders
4
last 12 mo
Over the past 12 months, insider activity at Tilray Brands, Inc. (TLRY) has been dominated by selling, with 3 insider purchases totaling $69.2K and 1 insider sale totaling $232.9K. The most recent insider transaction was by Gendel Mitchell (officer: Global General Counsel), who purchased $11.1K worth of shares on Aug 7, 2026. Tilray Brands, Inc. operates in the Healthcare sector, within the Drug Manufacturers - Specialty & Generic industry, with a market cap of $463.0M.
TLRY Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Aug 7, 2026 | Gendel Mitchell | officer: Global General Counsel | Buy | 2,500 | $4.43 | $11.1K | 124,883 |
| Aug 4, 2026 | FALTISCHEK DENISE M | officer: Chief Strategy Officer | Buy | 2,500 | $4.78 | $11.9K | 141,285 |
| Aug 4, 2026 | Merton Carl A | officer: Chief Financial Officer | Buy | 10,000 | $4.62 | $46.2K | 139,753 |
| Apr 22, 2026 | Hopkinson David G. | director | Sell | 33,556 | $6.94 | $232.9K | 0Exit |
| Aug 4, 2025 | Gendel Mitchell | Global General Counsel | Buy | 6,000 | $0.58 | $3.5K | 0 |
| Aug 4, 2025 | Merton Carl A | Chief Financial Officer | Sell | 49,782 | $0.58 | $28.9K | 0 |
| Aug 4, 2025 | SIMON IRWIN D | President and CEO | Sell | 374,295 | $0.58 | $217.1K | 0 |
| Jul 31, 2025 | FALTISCHEK DENISE M | Chief Strategy Officer | Sell | 138,433 | $0.61 | $84.4K | 0 |
| Jul 31, 2025 | Gendel Mitchell | Global General Counsel | Sell | 129,204 | $0.61 | $78.8K | 0 |
| Jul 31, 2025 | Herhalt Johann Michael | Director | Sell | 65,921 | $0.61 | $40.2K | 0 |
| Jul 31, 2025 | Merton Carl A | Chief Financial Officer | Sell | 88,276 | $0.61 | $53.8K | 0 |
| Jul 31, 2025 | SIMON IRWIN D | President and CEO | Sell | 623,528 | $0.61 | $380.4K0.6% OS | 0 |
| Jul 30, 2025 | Merton Carl A | Chief Financial Officer | Buy | 33,500 | $0.60 | $19.9K | 0 |
| Jul 30, 2025 | SIMON IRWIN D | President and CEO | Buy | 165,000 | $0.61 | $100.1K | 0 |
| Jun 4, 2025 | FALTISCHEK DENISE M | Chief Strategy Officer | Sell | 127,171 | $0.41 | $52.1K | 0 |
| Jun 4, 2025 | Gendel Mitchell | Global General Counsel | Sell | 117,922 | $0.41 | $48.3K | 0 |
| Jun 4, 2025 | Merton Carl A | Chief Financial Officer | Sell | 95,963 | $0.41 | $39.3K | 0 |
| Jun 4, 2025 | SIMON IRWIN D | President and CEO | Sell | 647,960 | $0.41 | $265.7K0.6% OS | 0 |
| Nov 18, 2024 | Merton Carl A | Chief Financial Officer | Buy | 26,000 | $1.36 | $35.4K | 26,000 |
| Jan 18, 2024 | FALTISCHEK DENISE M | Chief Strategy Officer | Buy | 10,000 | $2.05 | $20.5K | 293,269 |
| Jan 16, 2024 | Gendel Mitchell | Global General Counsel | Buy | 7,200 | $1.98 | $14.3K | 195,796 |
| Jan 12, 2024 | Gendel Mitchell | Global General Counsel | Buy | 5,400 | $1.87 | $10.1K | 188,596 |
| Jan 12, 2024 | Merton Carl A | Chief Financial Officer | Buy | 20,000 | $1.87 | $37.4K | 20,000 |
| Jan 12, 2024 | SIMON IRWIN D | President and CEO | Buy | 53,700 | $1.88 | $101.0K | 2,033,058 |
| Nov 9, 2022 | Kennedy Brendan | Director | Sell | 350,000 | $3.78 | $1.32M | 6,224,196 |
| Oct 7, 2022 | Kennedy Brendan | Director | Sell | 350,000 | $2.91 | $1.02M | 6,574,196 |
| Sep 8, 2022 | Kennedy Brendan | Director | Sell | 350,000 | $3.22 | $1.13M | 6,924,196 |
| Aug 9, 2022 | Kennedy Brendan | Director | Sell | 350,000 | $3.91 | $1.37M | 7,274,196 |
| Jul 7, 2022 | Kennedy Brendan | Director | Sell | 350,000 | $3.09 | $1.08M | 7,624,196 |
| Aug 6, 2021 | Kennedy Brendan | Sell | 600,000 | $14.27 | $8.56M0.6% OS | 8,274,196 | |
| Jul 19, 2021 | Kennedy Brendan | Sell | 600,000 | $14.35 | $8.61M0.6% OS | 8,950,485 | |
| Jun 24, 2021 | Kennedy Brendan | Sell | 800,000 | $17.58 | $14.06M0.8% OS | 9,574,196 | |
| Jun 7, 2021 | Meiers James R. | Head of Canada | Sell | 23,826 | $19.64 | $467.9K | 0Exit |
| May 14, 2021 | Merton Carl A | Chief Financial Officer | Sell | 89,000 | $14.82 | $1.32M | 169,105-34% |
TLRY Insider Buying Activity
The following table shows recent insider purchases of Tilray Brands, Inc. (TLRY) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Aug 7, 2026 | Gendel Mitchell | officer: Global General Counsel | Buy | 2,500 | $4.43 | $11.1K | 124,883 |
| Aug 4, 2026 | FALTISCHEK DENISE M | officer: Chief Strategy Officer | Buy | 2,500 | $4.78 | $11.9K | 141,285 |
| Aug 4, 2026 | Merton Carl A | officer: Chief Financial Officer | Buy | 10,000 | $4.62 | $46.2K | 139,753 |
| Aug 4, 2025 | Gendel Mitchell | Global General Counsel | Buy | 6,000 | $0.58 | $3.5K | 0 |
| Jul 30, 2025 | Merton Carl A | Chief Financial Officer | Buy | 33,500 | $0.60 | $19.9K | 0 |
| Jul 30, 2025 | SIMON IRWIN D | President and CEO | Buy | 165,000 | $0.61 | $100.1K | 0 |
| Nov 18, 2024 | Merton Carl A | Chief Financial Officer | Buy | 26,000 | $1.36 | $35.4K | 26,000 |
| Jan 18, 2024 | FALTISCHEK DENISE M | Chief Strategy Officer | Buy | 10,000 | $2.05 | $20.5K | 293,269 |
| Jan 16, 2024 | Gendel Mitchell | Global General Counsel | Buy | 7,200 | $1.98 | $14.3K | 195,796 |
| Jan 12, 2024 | Gendel Mitchell | Global General Counsel | Buy | 5,400 | $1.87 | $10.1K | 188,596 |
| Jan 12, 2024 | Merton Carl A | Chief Financial Officer | Buy | 20,000 | $1.87 | $37.4K | 20,000 |
| Jan 12, 2024 | SIMON IRWIN D | President and CEO | Buy | 53,700 | $1.88 | $101.0K | 2,033,058 |
TLRY Insider Selling Activity
The following table shows recent insider sales of Tilray Brands, Inc. (TLRY) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 22, 2026 | Hopkinson David G. | director | Sell | 33,556 | $6.94 | $232.9K | 0Exit |
| Aug 4, 2025 | Merton Carl A | Chief Financial Officer | Sell | 49,782 | $0.58 | $28.9K | 0 |
| Aug 4, 2025 | SIMON IRWIN D | President and CEO | Sell | 374,295 | $0.58 | $217.1K | 0 |
| Jul 31, 2025 | FALTISCHEK DENISE M | Chief Strategy Officer | Sell | 138,433 | $0.61 | $84.4K | 0 |
| Jul 31, 2025 | Gendel Mitchell | Global General Counsel | Sell | 129,204 | $0.61 | $78.8K | 0 |
| Jul 31, 2025 | Herhalt Johann Michael | Director | Sell | 65,921 | $0.61 | $40.2K | 0 |
| Jul 31, 2025 | Merton Carl A | Chief Financial Officer | Sell | 88,276 | $0.61 | $53.8K | 0 |
| Jul 31, 2025 | SIMON IRWIN D | President and CEO | Sell | 623,528 | $0.61 | $380.4K0.6% OS | 0 |
| Jun 4, 2025 | FALTISCHEK DENISE M | Chief Strategy Officer | Sell | 127,171 | $0.41 | $52.1K | 0 |
| Jun 4, 2025 | Gendel Mitchell | Global General Counsel | Sell | 117,922 | $0.41 | $48.3K | 0 |
| Jun 4, 2025 | Merton Carl A | Chief Financial Officer | Sell | 95,963 | $0.41 | $39.3K | 0 |
| Jun 4, 2025 | SIMON IRWIN D | President and CEO | Sell | 647,960 | $0.41 | $265.7K0.6% OS | 0 |
| Nov 9, 2022 | Kennedy Brendan | Director | Sell | 350,000 | $3.78 | $1.32M | 6,224,196 |
| Oct 7, 2022 | Kennedy Brendan | Director | Sell | 350,000 | $2.91 | $1.02M | 6,574,196 |
| Sep 8, 2022 | Kennedy Brendan | Director | Sell | 350,000 | $3.22 | $1.13M | 6,924,196 |
| Aug 9, 2022 | Kennedy Brendan | Director | Sell | 350,000 | $3.91 | $1.37M | 7,274,196 |
| Jul 7, 2022 | Kennedy Brendan | Director | Sell | 350,000 | $3.09 | $1.08M | 7,624,196 |
| Aug 6, 2021 | Kennedy Brendan | Sell | 600,000 | $14.27 | $8.56M0.6% OS | 8,274,196 | |
| Jul 19, 2021 | Kennedy Brendan | Sell | 600,000 | $14.35 | $8.61M0.6% OS | 8,950,485 | |
| Jun 24, 2021 | Kennedy Brendan | Sell | 800,000 | $17.58 | $14.06M0.8% OS | 9,574,196 | |
| Jun 7, 2021 | Meiers James R. | Head of Canada | Sell | 23,826 | $19.64 | $467.9K | 0Exit |
| May 14, 2021 | Merton Carl A | Chief Financial Officer | Sell | 89,000 | $14.82 | $1.32M | 169,105-34% |
TLRY Insiders
FALTISCHEK DENISE M
officer: Chief Strategy Officer
Bought $32.5KSold $136.6K
4 tradesLast: Aug 4, 2026
Similar Stocks to TLRY
VTRS
Viatris Inc.
$16.64-0.21%
$19.23B
ELAN
Elanco Animal Health Incorporated
$23.02-0.63%
$11.57B
AMRX
Amneal Pharmaceuticals, Inc.
$16.62-3.48%
$5.57B
INDV
Indivior Pharmaceuticals Inc
$34.10-1.06%
$4.36B
ETON
Eton Pharmaceuticals, Inc.
$54.59-5.26%
$1.61B
ANIP
ANI Pharmaceuticals, Inc.
$71.41+1.43%
$1.60B
HROW
Harrow Health, Inc.
$33.98-0.25%
$1.41B
PCRX
Pacira BioSciences, Inc.
$23.81-3.48%
$1.02B